China’s Sinovac Biotech on said late-stage trial data of its COVID-19 vaccine from Brazil and Turkey showed it prevented hospitalization and death in COVID-19 patients, but had a much lower efficacy rate in blocking infections, SİA reports citing Reuters.
The 12,396-person trial found the CoronaVac vaccine was 100% effective in preventing COVID-19 sufferers from being hospitalized or dying and 83.7% effective in avoiding cases that required any medical treatment, but only 50.65% effective at keeping people from getting infected, according to a statement.
The trials evaluated the efficacy of the two-shot vaccine candidate 14 days after inoculation of participants, including healthcare workers who treat COVID-19 patients.
In early January this year, Brazilian researchers reported interim results from the CoronaVac vaccine trial showing it was 50.4% effective at preventing symptomatic infections.
Efficacy rates of other vaccines have varied widely by country, an emerging pattern reflecting the impact of new variants.
Bütün xəbərlər Facebook səhifəmizdə
.jpg)
USD
EUR
GBP
RUB